Abstract
In “U.S. Patent Eligibility in the Wake of Bilski v Kappos: ‘Business as Usual’ in an Age of New Technologies?” by Timo Minssen & Robert M. Schwartz, 30 Biotech Law Report 6 (2011), footnote 9 should read as follows:
Cf. Christopher M. Holman, The impact of Bilski on biotechnology; available at http://holmansbiotechipblog.blogspot.com/2010/07/impact-of-bilski-on-biotechnology.html (last visited August 15, 2010)(adding, however, that these concerns were slightly alleviated by the Federal Circuit's narrow application of the test to claims on personalized drugs in Prometheus Labs, Inc v Mayo, 581 F.3d 1336 (Fed Cir 2009)).